<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002723</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02788</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CALGB-9480</secondary_id>
    <secondary_id>E-C9480</secondary_id>
    <secondary_id>SWOG-9452</secondary_id>
    <secondary_id>INT-0159</secondary_id>
    <secondary_id>CDR0000064583</secondary_id>
    <nct_id>NCT00002723</nct_id>
  </id_info>
  <brief_title>Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer</brief_title>
  <official_title>A PHASE III STUDY OF THREE DIFFERENT DOSES OF SURAMIN (NSC #34936) ADMINISTERED WITH A FIXED DOSING SCHEDULE IN PATIENTS WITH ADVANCED PROSTATE CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose
      suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy.
      Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
      growing or die. It is not yet known which regimen of suramin is more effective for prostate
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Compare the response in patients with advanced hormone-refractory adenocarcinoma of the
      prostate treated with low- vs intermediate- vs high-dose suramin.

      II. Compare the toxic effects of these regimens in these patients. III. Compare the overall
      and failure-free survival of patients treated with these regimens.

      IV. Compare the duration of complete and partial responses in patients treated with these
      regimens.

      V. Determine the population pharmacokinetics of these regimens and correlate these parameters
      with the toxicity of these regimens and response rate in these patients.

      VI. Compare the quality of life of patients treated with these regimens. VII. Determine the
      relationship of absolute and relative decrease in PSA and rate of PSA decrease with the
      likelihood and duration of response in patients treated with these regimens.

      VIII. Determine whether a change in fibroblast growth factor levels in patients treated with
      suramin can be associated with the pharmacokinetics of suramin or the likelihood of clinical
      response in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      disease site (bone only vs soft tissue), CALGB/Zubrod performance status (0 or 1 vs 2),
      number of prior hormonal therapies (1 or 2 vs 3), and participating center. Patients are
      randomized to 1 of 3 treatment arms.

      Arm I: Patients receive low-dose suramin IV over 1 hour on days 1, 2, 8, 9, 29, 30, 36, 37,
      57, 58, 64, and 65 in the absence of disease progression or unacceptable toxicity.

      Arm II: Patients receive intermediate-dose suramin as in arm I.

      Arm III: Patients receive high-dose suramin as in arm I. Patients with new progression after
      partial or complete response may receive additional courses, at the discretion of the study
      chairperson, beginning at least 12 weeks after completion of the first course and continuing
      in the absence of disease progression or unacceptable toxicity.

      Quality of life is assessed.

      Patients are followed every 4 weeks until disease progression and then periodically for new
      primary cancer(s) and survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1996</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>Week 12 and then monthly</time_frame>
    <description>PSA levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>Week 12 and every 12 weeks thereafter</time_frame>
    <description>Radiographic evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>pre-study, day 1, then every 2 weeks during treatment and every 8 weeks during follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>post treatment until patient expires</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>pre-study, 2 weeks post treatment, and every 12 weeks in follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Low dose suramin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose suramin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose suramin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose suramin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose suramin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose suramin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suramin</intervention_name>
    <description>3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.</description>
    <arm_group_label>Low dose suramin</arm_group_label>
    <other_name>NSC #34936</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suramin</intervention_name>
    <description>5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65</description>
    <arm_group_label>Intermediate dose suramin</arm_group_label>
    <other_name>NSC #34936</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suramin</intervention_name>
    <description>7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.</description>
    <arm_group_label>High dose suramin</arm_group_label>
    <other_name>NSC #34936</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven adenocarcinoma of the prostate with progressive metastatic or
             progressive regional nodal disease

               -  PSA evidence of progression defined as at least 50% increase over baseline on at
                  least 2 measurements at least 2 weeks apart

          -  Measurable disease preferred but not required

               -  Bone scan abnormalities acceptable provided PSA at least 10 ng/mL

               -  No minimum PSA value required if measurable disease present

          -  Progression after or during an adequate trial of hormonal therapy

          -  No more than 3 prior hormonal interventions for progressive disease

               -  One prior hormonal intervention is defined by any of the following:

                    -  Concurrent testicular and adrenal androgen ablation (e.g., leuprolide,
                       goserelin, orchiectomy, or diethylstilbestrol (DES) plus flutamide,
                       bicalutamide, nilutamide, megestrol, or other antiandrogen)

                    -  Initial LHRH agonist followed by orchiectomy provided no progression prior
                       to orchiectomy

                    -  Prior intermittent androgen deprivation on protocol SWOG-9346

                    -  Corticosteroids for metastatic disease or in conjunction with
                       aminoglutethimide or ketoconazole

               -  Two prior hormonal interventions are defined by the following:

                    -  Antiandrogen given for disease progression more than 3 months after initial
                       hormonal therapy

          -  Prior neoadjuvant or adjuvant deprivation for treatment of nonmetastatic disease not
             considered a prior hormonal intervention

          -  Antiandrogen withdrawal not considered a separate hormonal intervention

               -  At least 4 weeks since antiandrogen withdrawal or megestrol withdrawal

               -  Failure to respond to (i.e., no decrease in PSA at 2 and 4 weeks) or progression
                  after a transient response to antiandrogen withdrawal or megestrol withdrawal
                  required

          -  Primary testicular androgen suppression (e.g., LHRH agonist or DES) continues during
             study

          -  No brain metastases or other CNS disease

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  CALGB 0-2 OR

          -  Zubrod 0-2

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  WBC at least 3,000/mm3

          -  Absolute neutrophil count at least 1,200/mm3

          -  Platelet count at least 100,000/mm3

          -  Hemoglobin at least 9 g/dL

          -  Fibrinogen at least 200 mg/dL

          -  No prior hemorrhagic or thrombotic disorders

        Hepatic:

          -  Bilirubin normal

          -  AST/ALT no greater than 2.5 times normal

          -  Prothrombin time, partial thromboplastin time, and thrombin time normal

        Renal:

          -  Creatinine clearance at least 70 mL/min

        Other:

          -  No primary muscle disease

          -  No active, uncontrolled bacterial, viral, or fungal infection

          -  No grade 1 or worse peripheral neuropathy

          -  No underlying medical condition that would preclude study

          -  No other serious medical illness that limits survival to less than 3 months

          -  No psychiatric condition that would preclude informed consent

          -  No other malignancy within the past 5 years except inactive nonmelanomatous skin
             cancer or adequately treated stage I or II cancer in remission

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy for metastatic disease

        Chemotherapy:

          -  No prior chemotherapy (including estramustine) for metastatic disease

        Endocrine therapy:

          -  No concurrent megestrol or other hormonal agents

          -  No concurrent systemic or inhaled corticosteroids (intranasal and topical steroids
             allowed)

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy (8 weeks for strontium therapy)

        Other:

          -  No prior experimental therapy for metastatic disease

          -  No concurrent heparin, warfarin, or aspirin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric J. Small, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel P. Petrylak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Wilding, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Lakeside Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403-1206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Ann Arbor Regional</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - East Orange</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018-1095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Merit Care Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital Oncology Program</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Geisinger Clinic and Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - MainLine Health</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sioux Community Cancer Consortium</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Marshfield Medical Research and Education Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Milwaukee (Zablocki)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pretoria Academic Hospitals</name>
      <address>
        <city>Pretoria</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008 May 20;26(15):2544-9. doi: 10.1200/JCO.2007.15.0367.</citation>
    <PMID>18487572</PMID>
  </reference>
  <reference>
    <citation>D'Amico AV, Halabi S, Vogelzang NJ, et al.: A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: results of a pooled analysis of CALGB HRPC trials. [Abstract] J Clin Oncol 22 (Suppl 14): A-4506, 383s, 2004.</citation>
  </reference>
  <reference>
    <citation>Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003 Apr 1;21(7):1232-7. Erratum in: J Clin Oncol. 2004 Aug 15;22(16):3434.</citation>
    <PMID>12663709</PMID>
  </reference>
  <reference>
    <citation>Gilligan TD, Halabi S, Kantoff PW, et al.: African-American race is associated with longer survival in patients with metastatic hormone-refractory prostate cancer (HRCaP) in four randomized phase III Cancer and Leukemia Group B (CALGB) trials. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-725, 2002.</citation>
  </reference>
  <results_reference>
    <citation>George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005 Mar 1;11(5):1815-20.</citation>
    <PMID>15756004</PMID>
  </results_reference>
  <results_reference>
    <citation>Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005 Aug;66(2):386-91.</citation>
    <PMID>16098367</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahles TA, Herndon JE 2nd, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC; Cancer and Leukemia Group B. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15;101(10):2202-8.</citation>
    <PMID>15484217</PMID>
  </results_reference>
  <results_reference>
    <citation>Taplin ME, George DJ, Halabi S, et al.: Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. [Abstract] J Clin Oncol 22 (Suppl 14): A-4557, 396s, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15;20(16):3369-75.</citation>
    <PMID>12177096</PMID>
  </results_reference>
  <results_reference>
    <citation>Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001 Mar 15;61(6):2533-6.</citation>
    <PMID>11289126</PMID>
  </results_reference>
  <results_reference>
    <citation>George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW; Cancer and Leukemia Group B 9480. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001 Jul;7(7):1932-6.</citation>
    <PMID>11448906</PMID>
  </results_reference>
  <results_reference>
    <citation>Bok R, Halabi S, Shaal M, et al.: VEGF and basic FGF urine levels as predictors of response to therapy with suramin in CALGB 9480, a phase III study of hormone refractory prostate cancer (HRPC) patients. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1367, 2000.</citation>
  </results_reference>
  <results_reference>
    <citation>Halabi S, Small EJ, Ansari RH, et al.: Results of CALGB 9480, a phase III trial of 3 different doses of suramin for the treatment of horomone refractory prostate cancer (HRPC). [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1291, 2000.</citation>
  </results_reference>
  <results_reference>
    <citation>Kantoff P, Halabi S, Farmer D, et al.: RT-PCR for prostate specific antigen (PSA) in peripheral blood (PB) predicts survival duration in patients with hormone refractory prostate cancer (HRPC): a CALBG study. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A1323, 2000.</citation>
  </results_reference>
  <results_reference>
    <citation>Vogelzang N, Small E, Halabi R, et al.: A phase III trial of 3 different doses of suramin (SUR) in metastatic hormone refractory prostate cancer (HRPC): safety profile of CALGB 9480. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1339, 347a, 1998.</citation>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>October 21, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2003</study_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suramin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

